2026-03-16 10:14:16
Amphastar Pharmaceuticals Increases Share Buyback Program by $50 Million
Expected Stock impact: Slightly Positive
On March 12, 2026, Amphastar Pharmaceuticals, Inc. announced that its Board of Directors has authorized a significant increase of $50 million to the company's existing share buyback program. This decision is aimed at offsetting the dilution effects caused by the company's equity compensation programs. The buyback program is expected to continue indefinitely, allowing the company to repurchase shares through various means, including open market transactions and private negotiations, in compliance with SEC regulations. The timing and number of shares repurchased will depend on several factors, including market conditions and corporate requirements. This strategic move is anticipated to have a positive impact on the company's stock price, reflecting the Board's confidence in Amphastar's financial health and future prospects.
